This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589–97.
Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha. Blood. 2013;122:1464–77.
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652–60.
Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1317–24.
Malara A, Gruppi C, Abbonante V, Cattaneo D, De Marco L, Massa M, et al. EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. J Exp Med. 2019;216:587–604.
Villeval JL, Cohen-Solal K, Tulliez M, Giraudier S, Guichard J, Burstein SA, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90:4369–83.
Wagner-Ballon O, Chagraoui H, Prina E, Tulliez M, Milon G, Raslova H, et al. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. J Immunol (Baltim, Md : 1950). 2006;176:6425–33.
Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120:1202–9.
Dutta A, Nath D, Yang Y, Le BT, Mohi G. CDK6 is a therapeutic target in myelofibrosis. Cancer Res. 2021;81:4332–45.
Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, et al. CDK6 coordinates JAK2 (V617F) mutant MPN via NF-kappaB and apoptotic networks. Blood. 2019;133:1677–90.
Gilles L, Guieze R, Bluteau D, Cordette-Lagarde V, Lacout C, Favier R, et al. P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood. 2008;111:4081–91.
Hilpert M, Legrand C, Bluteau D, Balayn N, Betems A, Bluteau O, et al. p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging. Stem Cell Rep. 2014;3:1085–102.
Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel MF. INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol. 2000;20:372–8.
Rampal RK, Pinzon-Ortiz M, Somasundara AVH, Durham B, Koche R, Spitzer B, et al. Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms. Clin Cancer Res. 2021;27:3456–68.
Acknowledgements
We thank P. Rameau, C. Catelain, Y. Lecluse, T. Manoliu from the Imaging and cytometry platform PFIC and S. Souquere from Electronic microscopy platform, UMS3655-AMMICA, Gustave Roussy Villejuif, France; to O. Bawa, H. Rocheteau and N. Signolle for immunohistochemistry and immunofluorescence, and C. Metereau, L. Touchard for help with experiments on animals from preclinical research platform, PETRA, Gustave Roussy Villejuif, France; and to E. Pascal from INSERM U1176 for vWF dosage. This work was supported by grants from Ligue Nationale Contre le Cancer (Equipe labellisée 2016, 2019 and 2022 to HR) and MPN research foundation (IP). LG was supported by a fellowship from Association pour la recherche contre le cancer (ARC, France).
Author information
Authors and Affiliations
Contributions
HD, DM, LG, ALC, MEK, AK and IAD performed and analyzed experiments. FP provided patient samples. HD, DM, IAD, LG, ND, AK, FP, CM, RG, MW, VW, IP, HR discussed results. HR supervised the work. HD, DM, LG, VW, IP and HR wrote the article. DM and LG equally contributed to this work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Duparc, H., Muller, D., Gilles, L. et al. Deregulation of the p19/CDK4/CDK6 axis in Jak2V617F megakaryocytes accelerates the development of myelofibrosis. Leukemia 38, 898–902 (2024). https://doi.org/10.1038/s41375-024-02170-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-024-02170-5